Pliant Therapeutics, Inc.
PLRX
$1.33
$0.021.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -44.90% | -22.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -52.49% | -37.78% | |||
| Operating Income | 52.49% | 37.78% | |||
| Income Before Tax | 10.36% | 39.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.36% | 39.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.36% | 39.26% | |||
| EBIT | 52.49% | 37.78% | |||
| EBITDA | 53.06% | 38.13% | |||
| EPS Basic | 10.41% | 39.28% | |||
| Normalized Basic EPS | 55.90% | 39.06% | |||
| EPS Diluted | 10.41% | 39.28% | |||
| Normalized Diluted EPS | 55.90% | 39.06% | |||
| Average Basic Shares Outstanding | 0.07% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||